Conecte-se

Bibliografias temáticas / Inhibiteurs de JAK/STAT / Livros

Livros sobre o tema "Inhibiteurs de JAK/STAT"

Siga este link para ver outros tipos de publicações sobre o tema: Inhibiteurs de JAK/STAT.

Autor: Grafiati

Publicado: 22 de junho de 2024

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 26 melhores livros para estudos sobre o assunto "Inhibiteurs de JAK/STAT".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os livros das mais diversas áreas científicas e compile uma bibliografia correta.

1

Nicholson, Sandra E., e Nicos A. Nicola, eds. JAK-STAT Signalling. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-242-1.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Anastasis, Stephanou, ed. JAK-STAT pathway in disease. Austin, Tex: Landes Bioscience, 2009.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Decker, Thomas, e Mathias Müller, eds. Jak-Stat Signaling : From Basics to Disease. Vienna: Springer Vienna, 2012. http://dx.doi.org/10.1007/978-3-7091-0891-8.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Wilks, Andrew F., e Ailsa G. Harpur. Intracellular Signal Transduction: The JAK-STAT Pathway. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-662-22050-4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Wilks, Andrew F. Intracellular signal transduction: The JAK-STAT pathway. New York: Springer, 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. CRC Press, 2020.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Stephanou, Anastasis, e Bell Richard H. Jr. JAK-STAT Pathway in Disease. Taylor & Francis Group, 2009.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

H, Bell Jr Richard. JAK-STAT Pathway in Disease. Taylor & Francis Group, 2009.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Nicola, Nicos A., e Sandra E. Nicholson. JAK-STAT Signalling: Methods and Protocols. Humana Press, 2016.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Decker, Thomas, e Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer, 2012.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Harpur, Ailsa G., e Andrew F. Wilks. Intracellular Signal Transduction: The JAK-STAT Pathway. Springer, 2013.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Decker, Thomas, e Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer London, Limited, 2012.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Decker, Thomas, e Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer, 2012.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Decker, Thomas, e Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer Wien, 2014.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Wilks, Andrew F. Intracellular Signal Transduction: The Jak-Stat Pathway. Springer, 2013.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

The Jak-Stat pathway in hematopoiesis and disease. Georgetown, Tex: Landes Bioscience/Eurekah.com, 2002.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Harpur, Ailsa G., e Andrew F. Wilks. The Jak-Stat Pathway (Molecular Biology Intelligence Unit). Springer, 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Ward, Alister C. The Jak-Stat Pathway in Hematopoiesis and Disease (Molecular Biology Intelligence Unit, 20). Springer, 2002.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Ng, Sze-Ling. The Role of IKKepsilon in JAK/STAT Signaling During the Antiviral Immune Response. 2010.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Mahdavi, Alborz. Analysis of transient JAK/STAT signaling kinetics predicts control modules of stem cell fate control. 2006.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Jakstat Signalling Methods And Protocols. Humana Press, 2012.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Fleischmann, Roy. Signalling pathway inhibitors. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081.

Texto completo da fonte

Resumo:

Oral, small-molecule signalling pathway inhibitors, including ones that inhibit the JAK and SyK pathways, are currently in development for the treatment of rheumatoid arthritis (RA). Tofacitinib is an orally administered small-molecule inhibitor that targets the intracellular Janus kinase 3 and 1 (JAK1/3) molecules to a greater extent than JAK2 while baricitinib (formerly INCB028050) predominantly inhibits JAK1/2. Many of the proinflammatory cytokines implicated in the pathogenesis of RA utilize cell signalling that involves the JAK-STAT pathways and therefore inhibition of JAK-STAT signalling, by targeting multiple RA-associated cytokine pathways, has the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key immune cells. Fostamatinib disodium is an orally available inhibitor of spleen tyrosine kinase (SyK), which is a cytoplasmic tyrosine kinase that is an important mediator of immunoreceptor signalling in mast cells, macrophages, neutrophils, and B cells. Interruption of SyK signalling may interrupt production of tumour necrosis factor (TNF) and metalloproteinase and therefore affect RA disease activity. Tofacitinib has been investigated in multiple phase 2 and phase 3 trials which have investigated its efficacy (clinical, functional, and radiographic) and safety in patients who have failed disease-modifying anti-inflammatory drugs (DMARDs) as monotherapy or in combination with DMARDs, compared to an inhibitor of tumour necrosis factor alpha (TNFα‎) and in patients who have failed TNFα‎ inhibitors. The efficacy of fostamatinib and baricitinib has been investigated in phase 2 trials; both are in large phase 3 clinical programmes. Each of these medications has demonstrated efficacy; their safety profile has been shown to be different from each other and from currently approved biological agents. This chapter discusses what is currently known and understood about their efficacy and safety.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!